Fine chemical industry includes fine chemicals and special chemicals, fine chemical products have a small amount of production, application field is relatively specific, industry chain is long and complex characteristics, mainly used in medicine, pesticides, dyes, liquid crystal and other fields. After nearly ten years' growth, China's fine chemical industry has made considerable progress, and the overall fine chemical production rate (that is, fine chemical product output value = total fine chemical product value / chemical product total value of 100%) is about 40%. Some fine chemical products have a certain international competitive power and become important processing and export places of fine chemical raw materials and intermediates in the world. However, compared with the 60-70% precision rate of the developed economies such as North America, Western Europe and Japan, China is still equal to the level of the United States in the 1980s, and there is still a lot of room for the improvement of the refinement rate in our country.

  There is still a lot of room for development in our country's pharmaceutical intermediates industry. Chemical enterprises should find a way suitable for their own development.

1. Product diversification and extension to the high end of the industrial chain 

  From the production of extensive low-end intermediates to fine high-end intermediates, and to other areas of pharmaceutical services. This has higher requirements to the management and technical strength of the company, but also needs to accumulate customer credibility, cooperation time also has a great impact on the depth of cooperation.

2. Global and China industry concentration is low.

   China CMO and CRO still have a lot of room for growth, global and China industry concentration is low. Pharmaceutical intermediates are not subject to patent protection and do not need GMP certification, so the threshold of entry is relatively low, and there are many kinds of products. Therefore, the degree of industry concentration is low, and the outsourcing of pharmaceutical intermediates is no exception.